IP Library › Granted Patent US 11,401,501
Granted Patent B2
US 11,401,501 · App. 16/316,573 · Granted Aug 2, 2022

Methods for culturing organoids

Inventors: Marianne J. Ellis (Caerdydd, GB); Julian Chaudhuri (Caerdydd, GB); Trevor Clive Dale (Caerdydd, GB)
Assignee: CELLESCE LIMITED
C12N5/0081C12N5/0062C12N5/0679C12N2509/10C12N2513/00C12N2533/00C12N2533/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,401,501
App. No.
16/316,573
Granted
Aug 2, 2022
Kind
B2
Abstract

The present invention provides a method for culturing organoids, the method comprising: a) disassociating unprocessed organoids to produce a cell suspension; b) sieving the cell suspension through a cell strainer to retain a sieved cell suspension containing cells of about 10 μm to about 1 mm in diameter; and c) seeding cells of the sieved cell suspension into a bioreactor in a cell culture medium comprising an extracellular support matrix.

Claims (19)

1. A method for culturing organoids, the method comprising:

a) disassociating unprocessed organoids from primary cultures of tissue samples to produce a cell suspension;

b) sieving the cell suspension through a cell strainer to retain a sieved cell suspension containing cells of about 10 μm to about 1 mm in diameter;

c) seeding cells of the sieved cell suspension into a bioreactor in a cell culture medium comprising an extracellular support matrix;

d) culturing the cells in the bioreactor to form stage I organoids;

e) removing the stage I organoids from the bioreactor and suspending the stage I organoids in cell culture medium to form an organoid suspension; and

f) sieving the organoid suspension through at least two cell strainers having different mesh sizes to obtain a suspension of stage II organoids having a diameter of about 20 μm to about 200 μm.

2. The method of claim 1 , wherein the bioreactor is a perfusion bioreactor.

3. The method of claim 1 , wherein the bioreactor is a fed-plate bioreactor.

4. The method of claim of claim 1 , wherein the fed-plate bioreactor is a flat-bed bioreactor.

5. A method according to claim 3 , wherein the fed-plate bioreactor comprises an arrangement of bioreactors that are fed in parallel.

6. The method of claim 1 , wherein the cell culture medium comprises about 1% to about 99% v/v of the extracellular support matrix.

7. The method of claim 1 , wherein the cell culture medium comprises about 5% to about 85% v/v of the extracellular support matrix.

8. The method of claim 1 , wherein the extracellular support matrix is a solubilized basement membrane preparation.

9. The method of claim 1 , wherein the extracellular support matrix comprises laminin, entactin and collagen IV or laminin, entactin, collagen IV and heparin sulphate proteoglycan.

10. The method of claim 1 , wherein the cell strainer of step (b) has a mesh size of about 30 μm to about 50 μm.

11. The method of claim 1 , wherein step (e) comprises incubating the stage I organoids with cell recovery solution before suspending the organoids in cell culture medium.

12. The method of claim 1 , wherein the cell strainers of step (f) have mesh sizes of about 40 μm and about 85 μm.

13. The method of claim 1 , further comprising freezing the stage II organoids.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: CELLESCE LIMITED
To: MOLECULAR DEVICES (UK) LIMITED
Reel/Frame 067222/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: ELLIS, MARIANNE J; CHAUDHURI, JULIAN; DALE, TREVOR CLIVE
To: CELLESCE LIMITED
Reel/Frame 047945/0309 →
Priority Claims (1)
GB 1611982 · Jul 11, 2016 · national
Continuity (1)
Related Publication 20190249137A1 · Aug 15, 2019